Sangrix Statistics
Total Valuation
Sangrix has a market cap or net worth of $676,343. The enterprise value is $14.62 million.
| Market Cap | 676,343 |
| Enterprise Value | 14.62M |
Important Dates
The next estimated earnings date is Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Sangrix has 322,068 shares outstanding. The number of shares has increased by 698.41% in one year.
| Current Share Class | 319,508 |
| Shares Outstanding | 322,068 |
| Shares Change (YoY) | +698.41% |
| Shares Change (QoQ) | +117.64% |
| Owned by Insiders (%) | 0.79% |
| Owned by Institutions (%) | 2.30% |
| Float | 319,508 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.98 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 369.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 44.93
| Current Ratio | 44.93 |
| Quick Ratio | 5.74 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.49 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -72.44% |
| Return on Invested Capital (ROIC) | -77.76% |
| Return on Capital Employed (ROCE) | -77.76% |
| Weighted Average Cost of Capital (WACC) | 3.74% |
| Revenue Per Employee | $7,899 |
| Profits Per Employee | -$4.42M |
| Employee Count | 5 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.12% in the last 52 weeks. The beta is 1.90, so Sangrix's price volatility has been higher than the market average.
| Beta (5Y) | 1.90 |
| 52-Week Price Change | -98.12% |
| 50-Day Moving Average | 4.33 |
| 200-Day Moving Average | 21.15 |
| Relative Strength Index (RSI) | 23.20 |
| Average Volume (20 Days) | 1,142,995 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sangrix had revenue of $39,495 and -$22.11 million in losses. Loss per share was -$109.86.
| Revenue | 39,495 |
| Gross Profit | 39,495 |
| Operating Income | -9.82M |
| Pretax Income | -22.05M |
| Net Income | -22.11M |
| EBITDA | n/a |
| EBIT | -9.82M |
| Loss Per Share | -$109.86 |
Balance Sheet
The company has $484,970 in cash and $14.43 million in debt, with a net cash position of -$13.95 million or -$43.31 per share.
| Cash & Cash Equivalents | 484,970 |
| Total Debt | 14.43M |
| Net Cash | -13.95M |
| Net Cash Per Share | -$43.31 |
| Equity (Book Value) | -1.80M |
| Book Value Per Share | -3.69 |
| Working Capital | 12.43M |
Cash Flow
| Operating Cash Flow | -1.45M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 3.91M |
| Free Cash Flow | -1.45M |
| FCF Per Share | -$4.51 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -24,865.89% |
| Pretax Margin | -55,833.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Sangrix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -698.41% |
| Shareholder Yield | -698.41% |
| Earnings Yield | -3,502.85% |
| FCF Yield | -230.18% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 21, 2026. It was a reverse split with a ratio of 1:5.
| Last Split Date | Aug 21, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
Sangrix has an Altman Z-Score of -12.25 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.25 |
| Piotroski F-Score | 2 |